Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

ASH 2024 Insights: POLARIX 5yr Update - Pola-R-CHP vs. R-CHOP in 1L …

2024 ASH Annual Meeting Insights Hub

G. Salles

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

DLBCL: Treatment Options for Transplant-Ineligible Patients

Amit Mehta

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

Georg Lenz

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

What's Current in Immunotherapy in DLBCL and FL

Houston Methodist

A. Mehta

2024 Updates in the Management of DLBCL, FL, and HL

UNC Lineberger Comprehensive Cancer Center

A. Beaven

Frontline DLBCL Treatment Approaches

MyCancerHaven

R. Vij, H. Cherng

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

Juan Pablo Alderuccio